Unichem Joins Growing List of Indian Firms Entering China
Unichem Laboratories has joined a growing list of Indian firms entering China. The firm has set up a wholly-owned subsidiary to sell generic formulations and APIs.
You may also be interested in...
Acquiring Unichem Laboratories’ branded formulations business in India helped Torrent Pharmaceuticals to achieve sales growth of over a third in its domestic market to Rs8.16 billion (US$112 million) in the Indian firm’s financial second quarter ended 30 September 2018.
The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.
Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.